HER2 Positivity Predicts Unresponsiveness to EGFR‐Targeted Treatment in Metastatic Colorectal Cancer

BACKGROUND. HER2 amplification is detected in 3% of patients with colorectal cancer (CRC), making tumors in the metastatic setting vulnerable to double pharmacological HER2 blockade. Preclinical findings show that it also might impair response to anti‐epidermal growth factor receptor (EGFR) treatmen...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncologist
Huvudupphovsmän: Sartore‐Bianchi, Andrea, Amatu, Alessio, Porcu, Luca, Ghezzi, Silvia, Lonardi, Sara, Leone, Francesco, Bergamo, Francesca, Fenocchio, Elisabetta, Martinelli, Erika, Borelli, Beatrice, Tosi, Federica, Racca, Patrizia, Valtorta, Emanuele, Bonoldi, Emanuela, Martino, Cosimo, Vaghi, Caterina, Marrapese, Giovanna, Ciardiello, Fortunato, Zagonel, Vittorina, Bardelli, Alberto, Trusolino, Livio, Torri, Valter, Marsoni, Silvia, Siena, Salvatore
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley & Sons, Inc. 2019
Ämnen:
Gastrointestinal Cancer
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795149/
https://ncbi.nlm.nih.gov/pubmed/30952821
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0785
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk